Summary of disease group classifications by diagnosis source
| Diagnosis source . | Disease groups (N = 918) . | ||||||
|---|---|---|---|---|---|---|---|
| MDS . | MDS/MPN overlap . | ICUS . | AML with <30% blasts∗ . | Other AML . | Other malignancy . | Other . | |
| Original local diagnosis | 264 (29%) | 15 (2%) | 62 (7%) | 0 (0%) | 46 (5%) | 49 (5%) | 482 (53%) |
| Validated local diagnosis | 255 (28%) | 33 (4%) | 56 (6%) | 12 (1%) | 42 (5%) | 82 (9%) | 438 (48%) |
| Final study diagnosis | 266 (29%) | 45 (5%) | 49 (5%) | 15 (2%) | 38 (4%) | 93 (10%) | 412 (45%) |
| Diagnosis source . | Disease groups (N = 918) . | ||||||
|---|---|---|---|---|---|---|---|
| MDS . | MDS/MPN overlap . | ICUS . | AML with <30% blasts∗ . | Other AML . | Other malignancy . | Other . | |
| Original local diagnosis | 264 (29%) | 15 (2%) | 62 (7%) | 0 (0%) | 46 (5%) | 49 (5%) | 482 (53%) |
| Validated local diagnosis | 255 (28%) | 33 (4%) | 56 (6%) | 12 (1%) | 42 (5%) | 82 (9%) | 438 (48%) |
| Final study diagnosis | 266 (29%) | 45 (5%) | 49 (5%) | 15 (2%) | 38 (4%) | 93 (10%) | 412 (45%) |
Denominator in percentage represents the number participants who underwent centralized pathology review.
N, number of participants who underwent centralized pathology review.
AML with <30% blasts without core binding factor or acute promyelocytic leukemia.